Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$3.63M$3.63Mno prior Q1 2016 on file Net Income-$50.33M-$50.33MN/M vs Q1 2016 EPS Diluted-$1.00-$1.00N/M vs Q1 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$50,581,000N/M Free Cash Flowderived-$51,519,000N/M Margins · derivedGross margin67.3%
Operating margin-1357.4%
Net margin-1385.7%
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end